Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-H0731 + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- Assembly Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ABI-H0731 + tenofovir disoproxil fumarate** is a combination therapy under development for the treatment of chronic hepatitis B virus (HBV) infection. **ABI-H0731** is a first-generation small molecule inhibitor of the HBV core protein that interferes with viral replication by blocking core protein assembly, preventing pregenomic RNA (pgRNA) encapsidation, and inhibiting covalently closed circular DNA (cccDNA) formation, thereby preventing new HBV formation and the maintenance of the virus in infected cells[1][3][5]. **Tenofovir disoproxil fumarate** is a nucleotide analog reverse transcriptase inhibitor (NtRTI) that inhibits HBV reverse transcriptase and prevents viral DNA chain elongation, acting as a primary backbone therapy for HBV and HIV-1 infections[2][4]. The combination is investigated for additive or synergistic reductions in HBV viral load, aiming for greater antiviral activity than either agent alone.
- Other names
- tenofovir disoproxil fumarateTDF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on ABI-H0731 + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-H0731 + tenofovir disoproxil fumarate.